April 24, 2018 11:52 PM ET

Biotechnology

Company Overview of ACADIA Pharmaceuticals Inc.

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

3611 Valley Centre Drive

Suite 300

San Diego, CA 92130

United States

Founded in 1993

425 Employees

Phone:

858-558-2871

Fax:

858-558-2872

Key Executives for ACADIA Pharmaceuticals Inc.

President, CEO & Director
Age: 56
Total Annual Compensation: $1.1M
Executive VP, CFO & Principal Accounting Officer
Age: 45
Total Annual Compensation: $208.8K
Head of Research & Development and Executive Vice President
Age: 60
Total Annual Compensation: $694.7K
Executive Vice President, General Counsel and Secretary
Age: 47
Total Annual Compensation: $576.4K
Compensation as of Fiscal Year 2016.

ACADIA Pharmaceuticals Inc. Key Developments

ACADIA Pharmaceuticals Inc. Presents at Needham and Company 17th Annual Healthcare Conference, Mar-27-2018 11:30 AM

ACADIA Pharmaceuticals Inc. Presents at Needham and Company 17th Annual Healthcare Conference, Mar-27-2018 11:30 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

ACADIA Pharmaceuticals Inc. Report Earnings Results for the Fourth Quarter and Full Year of 2017: Provides Sales Guidance for the First Quarter and Full Year 2018

ACADIA Pharmaceuticals Inc. reported earnings results for the fourth quarter and full year of 2017. For the quarter, the company reported total revenue of $43,562,000 against $11,962,000 a year ago. Loss from operations was $70,009,000 against $78,231,000 a year ago. Loss before income taxes was $68,902,000 against $77,355,000 a year ago. Net loss was $68,871,000 or $0.55 per basic and diluted share against $78,696,000 or $0.65 per basic and diluted share a year ago. Cash used in operations was approximately $30 million. For the year, the company reported total revenue of $124,901,000 against $17,331,000 a year ago. Loss from operations was $292,410,000 against $272,815,000 a year ago. Loss before income taxes was $288,284,000 against $270,052,000 a year ago. Net loss was $289,403,000 or $2.36 per basic and diluted share against $271,393,000 or $2.34 per basic and diluted share a year ago. For the first quarter 2018, net sales are expected to be in the range of $45 million to $48 million. For 2018, it expects NUPLAZID net product sales will be between $255 million and $270 million, adding that it expects to end 2018 with more than $200 million of cash, cash equivalents and investment securities on its balance sheet.

ACADIA Pharmaceuticals Inc. to Report Q4, 2017 Results on Feb 27, 2018

ACADIA Pharmaceuticals Inc. announced that they will report Q4, 2017 results at 5:00 PM, US Eastern Standard Time on Feb 27, 2018

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ACADIA Pharmaceuticals Inc., please visit www.acadia-pharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.